DNMT3A and rheumatoid arthritis: Encouraged by the in vivo bioactivity of PCL scaffold–delivered progenitors, we moved on to employ the scaffolds loaded with epigenetically modified dCas9-Dnmt3a-Rbpjk1-9 C3H10T1/2 cells (3 × 105 cells/cm3) in RA fractures.